Literature DB >> 11549302

Prognostic value of serum gamma-glutamyl transferase activity after myocardial infarction.

M Emdin1, C Passino, C Michelassi, F Titta, A L'abbate, L Donato, A Pompella, A Paolicchi.   

Abstract

AIMS: Serum gamma-glutamyl transferase activity (gamma-GT) is able to catalyse low-density lipoprotein oxidation and has been detected in coronary atherosclerotic plaques. gamma-GT has been documented as an independent risk factor for cardiac mortality in middle-aged men. The purpose of this study is to determine the prognostic value of gamma-GT in patients with coronary artery disease. METHODS AND
RESULTS: In a prospective study, gamma-GT and other cardiac risk factors were evaluated in 469 consecutive subjects with angiographically documented coronary artery disease, using mortality and mortality plus non-fatal myocardial infarction as end-points. gamma-GT showed an independent prognostic value beyond known established risk factors in the subgroup of 262 patients with previous myocardial infarction. At a 6-year follow-up, cardiac mortality was 25.2% in patients with gamma-GT >40 U x l(-1)vs 13.9% in those with gamma-GT <40 U x l(-1)(P=0.038). When both cardiac mortality and non-fatal myocardial infarction were considered as end-points, these events were recorded in 32.7% of patients with gamma-GT >40 U x l(-1)and in 20.4% of those with levels <40 U x l(-1)(P=0.031). Excess mortality and non-fatal infarction in patients with high gamma-GT levels were concentrated in the first 2 years of follow-up (P=0.014). The association of gamma-GT values >40 U x l(-1), previous myocardial infarction, and multiple vessel disease identified a subgroup of 168 patients with the highest risk of cardiac events at 6 years (P=0.024). The relationship between gamma-GT levels and cardiac events remained significant after adjustment for cardiac risk factors, and possible confounders, including alcohol consumption. gamma-GT did not show significant prognostic value in the 207 patients without previous myocardial infarction.
CONCLUSION: gamma-GT is an independent cardiac risk factor in ischaemic patients with established coronary atherosclerosis and previous myocardial infarction. Copyright 2001 The European Society of Cardiology.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549302     DOI: 10.1053/euhj.2001.2807

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  23 in total

1.  Serum gamma-glutamyl transferase and risk of heart failure in the community.

Authors:  Ravi Dhingra; Philimon Gona; Thomas J Wang; Caroline S Fox; Ralph B D'Agostino; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-06-10       Impact factor: 8.311

Review 2.  Gamma-glutamyl transferase and cardiovascular disease.

Authors:  Gjin Ndrepepa; Adnan Kastrati
Journal:  Ann Transl Med       Date:  2016-12

3.  The prognostic role of gamma-glutamyltransferase activity in non-diabetic ST-elevation myocardial infarction.

Authors:  Chiara Lazzeri; Serafina Valente; Roberto Tarquini; Marco Chiostri; Claudio Picariello; Gian Franco Gensini
Journal:  Intern Emerg Med       Date:  2010-09-29       Impact factor: 3.397

4.  Correlates and reference limits of plasma gamma-glutamyltransferase fractions from the Framingham Heart Study.

Authors:  Maria Franzini; Irene Fornaciari; Jian Rong; Martin G Larson; Claudio Passino; Michele Emdin; Aldo Paolicchi; Ramachandran S Vasan
Journal:  Clin Chim Acta       Date:  2012-12-14       Impact factor: 3.786

5.  Serum gamma-glutamyltransferase levels are inversely related to endothelial function in chronic kidney disease.

Authors:  Mahmut Ilker Yilmaz; Faruk Turgut; Mehmet Kanbay; Mutlu Saglam; Alper Sonmez; Halil Yaman; Seref Demirbas; Hilmi Umut Unal; Mahmut Gok; Murat Karaman; Seyit Ahmet Ay; Erkan Demirkaya; Adrian Covic; Juan Jesus Carrero
Journal:  Int Urol Nephrol       Date:  2012-12-15       Impact factor: 2.370

6.  The association of higher levels of within-normal-limits liver enzymes and the prevalence of the metabolic syndrome.

Authors:  Arie Steinvil; Itzhak Shapira; Orit Kliuk Ben-Bassat; Michael Cohen; Yaffa Vered; Shlomo Berliner; Ori Rogowski
Journal:  Cardiovasc Diabetol       Date:  2010-07-15       Impact factor: 9.951

Review 7.  Role of gamma-glutamyltransferase in cardiovascular diseases.

Authors:  Shengyang Jiang; Donglin Jiang; Yijia Tao
Journal:  Exp Clin Cardiol       Date:  2013

8.  Longitudinal change in serum gamma-glutamyltransferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults.

Authors:  Alexander M Strasak; Cecily C Kelleher; Jochen Klenk; Larry J Brant; Elfriede Ruttmann; Kilian Rapp; Hans Concin; Günter Diem; Karl P Pfeiffer; Hanno Ulmer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-10       Impact factor: 8.311

9.  Association of gamma-glutamyltransferase and risk of cancer incidence in men: a prospective study.

Authors:  Alexander M Strasak; Kilian Rapp; Larry J Brant; Wolfgang Hilbe; Martin Gregory; Willi Oberaigner; Elfriede Ruttmann; Hans Concin; Günter Diem; Karl P Pfeiffer; Hanno Ulmer
Journal:  Cancer Res       Date:  2008-05-15       Impact factor: 12.701

10.  Incremental predictive value of red cell distribution width for 12-month clinical outcome after acute myocardial infarction.

Authors:  Jang Hoon Lee; Dong Heon Yang; Se Yong Jang; Won Suk Choi; Kyun Hee Kim; Won Kee Lee; Myung Hwan Bae; Hun Sik Park; Yongkeun Cho; Shung Chull Chae
Journal:  Clin Cardiol       Date:  2013-04-08       Impact factor: 2.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.